Enanta Pharmaceuticals Stock Performance
| ENTA Stock | USD 13.89 0.03 0.22% |
Enanta Pharmaceuticals has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.067, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Enanta Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Enanta Pharmaceuticals is likely to outperform the market. Enanta Pharmaceuticals right now shows a risk of 2.9%. Please confirm Enanta Pharmaceuticals semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to decide if Enanta Pharmaceuticals will be following its price patterns.
Risk-Adjusted Performance
Mild
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Enanta Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Enanta Pharmaceuticals is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors. ...more
Actual Historical Performance (%)
One Day Return 0.79 | Five Day Return 1.16 | Year To Date Return (2.91) | Ten Year Return (51.17) | All Time Return (18.51) |
1 | Acquisition by Jay Luly of 310000 shares of Enanta Pharmaceuticals at 13.66 subject to Rule 16b-3 | 11/25/2025 |
2 | Acquisition by Scott Rottinghaus of 110000 shares of Enanta Pharmaceuticals at 13.66 subject to Rule 16b-3 | 11/28/2025 |
3 | Will Enanta Pharmaceuticals Inc. stock benefit from upcoming earnings reports - Rate Hike Accurate Technical Buy Alerts - Blm Sonu Canavar | 12/19/2025 |
4 | What makes Enanta Pharmaceuticals Inc. stock attractive to growth funds - Market Sentiment Extremes Minimal Capital Appreciation - Bollywood Helpline | 12/23/2025 |
5 | Enanta Pharmaceuticals, Inc. Receives 20.33 Average Price Target from Brokerages | 12/29/2025 |
6 | Enanta Pharmaceuticals Is Exploding On Watchlists But Is ENTA Stock Actually Worth Your Money - AD HOC NEWS | 01/07/2026 |
7 | JPM26 Enanta outlines strategy to lead in RSV therapeutics | 01/15/2026 |
8 | Enanta seeks 1.6M-share boost to 2019 equity plan - Stock Titan | 01/26/2026 |
9 | Enanta Pharmaceuticals Fiscal Q1 Earnings Snapshot | 02/09/2026 |
10 | Enanta Pharmaceuticals Quarterly Loss Narrows Yet Keeps Profitability Concerns In Investor Focus | 02/11/2026 |
11 | Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts | 02/12/2026 |
| Begin Period Cash Flow | 41.2 M | |
| Total Cashflows From Investing Activities | 40.3 M |
Enanta Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 1,365 in Enanta Pharmaceuticals on November 22, 2025 and sell it today you would earn a total of 24.00 from holding Enanta Pharmaceuticals or generate 1.76% return on investment over 90 days. Enanta Pharmaceuticals is currently generating 0.0711% in daily expected returns and assumes 2.9001% risk (volatility on return distribution) over the 90 days horizon. In different words, 26% of stocks are less volatile than Enanta, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Enanta Pharmaceuticals Target Price Odds to finish over Current Price
The tendency of Enanta Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 13.89 | 90 days | 13.89 | about 47.23 |
Based on a normal probability distribution, the odds of Enanta Pharmaceuticals to move above the current price in 90 days from now is about 47.23 (This Enanta Pharmaceuticals probability density function shows the probability of Enanta Stock to fall within a particular range of prices over 90 days) .
Enanta Pharmaceuticals Price Density |
| Price |
Predictive Modules for Enanta Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Enanta Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Enanta Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Enanta Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Enanta Pharmaceuticals is not an exception. The market had few large corrections towards the Enanta Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Enanta Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Enanta Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.27 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 1.15 | |
Ir | Information ratio | 0.07 |
Enanta Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Enanta Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Enanta Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Enanta Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 65.32 M. Net Loss for the year was (81.89 M) with profit before overhead, payroll, taxes, and interest of 66.98 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (19.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22. | |
| Enanta Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts |
Enanta Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Enanta Stock often depends not only on the future outlook of the current and potential Enanta Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Enanta Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 21.3 M | |
| Cash And Short Term Investments | 188.9 M |
Enanta Pharmaceuticals Fundamentals Growth
Enanta Stock prices reflect investors' perceptions of the future prospects and financial health of Enanta Pharmaceuticals, and Enanta Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Enanta Stock performance.
| Return On Equity | -0.6 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (1.07) % | ||||
| Operating Margin | (0.60) % | ||||
| Current Valuation | 273.14 M | ||||
| Shares Outstanding | 29.02 M | ||||
| Price To Earning | 366.13 X | ||||
| Price To Book | 3.17 X | ||||
| Price To Sales | 6.07 X | ||||
| Revenue | 65.32 M | ||||
| Gross Profit | 66.98 M | ||||
| EBITDA | (70.78 M) | ||||
| Net Income | (81.89 M) | ||||
| Cash And Equivalents | 253.29 M | ||||
| Cash Per Share | 12.22 X | ||||
| Total Debt | 201.06 M | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 13.59 X | ||||
| Book Value Per Share | 4.36 X | ||||
| Cash Flow From Operations | (19.27 M) | ||||
| Earnings Per Share | (3.24) X | ||||
| Market Capitalization | 406.27 M | ||||
| Total Asset | 280.73 M | ||||
| Retained Earnings | (404.93 M) | ||||
| Working Capital | 155.78 M | ||||
| Current Asset | 241.79 M | ||||
| Current Liabilities | 9.57 M | ||||
About Enanta Pharmaceuticals Performance
By analyzing Enanta Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Enanta Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Enanta Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Enanta Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.42) | (0.40) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (1.46) | (1.38) |
Things to note about Enanta Pharmaceuticals performance evaluation
Checking the ongoing alerts about Enanta Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Enanta Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Enanta Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 65.32 M. Net Loss for the year was (81.89 M) with profit before overhead, payroll, taxes, and interest of 66.98 M. | |
| Enanta Pharmaceuticals currently holds about 253.29 M in cash with (19.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.22. | |
| Enanta Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Over 91.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Enanta Pharmaceuticals, Inc. Given Average Recommendation of Moderate Buy by Analysts |
- Analyzing Enanta Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Enanta Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Enanta Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Enanta Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Enanta Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Enanta Pharmaceuticals' stock. These opinions can provide insight into Enanta Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Enanta Stock analysis
When running Enanta Pharmaceuticals' price analysis, check to measure Enanta Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Enanta Pharmaceuticals is operating at the current time. Most of Enanta Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Enanta Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Enanta Pharmaceuticals' price. Additionally, you may evaluate how the addition of Enanta Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |